<DOC>
	<DOCNO>NCT00281957</DOCNO>
	<brief_summary>This randomized phase II trial study well give sorafenib together either temsirolimus tipifarnib work treat patient stage IV melanoma remove surgery . Sorafenib , temsirolimus , tipifarnib may stop growth tumor cell block enzymes need cell growth . Sorafenib tipifarnib may also stop growth tumor block blood flow tumor . It yet know whether sorafenib effective give together temsirolimus tipifarnib treat patient malignant melanoma .</brief_summary>
	<brief_title>Sorafenib With Either Temsirolimus Tipifarnib Treating Patients With Stage IV Malignant Melanoma That Can Be Removed By Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare response rate ( confirm unconfirmed complete partial ) patient unresectable stage IV malignant melanoma treat sorafenib combination either temsirolimus tipifarnib . II . Compare 4-month progression-free survival rate patient treat regimen . III . Compare safety tolerability regimen , emphasis long-term side effect toxic effect , patient . OUTLINE : This randomize , multicenter study . Patients stratify accord metastatic ( M ) stage ( M1a/b v M1c ) . Patients randomize 1 2 treatment arm . ARM I ( reopen accrual 8/15/2009 ) : Patients receive oral sorafenib twice daily day 1-28 temsirolimus IV 30 minute day 1 , 8 , 15 , 22 . ARM II ( close accrual 8/15/2009 ) : Patients receive oral sorafenib arm I oral tipifarnib twice daily day 1-21 . In arm , course repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Criteria : Histologically confirm malignant melanoma cutaneous origin Patients unknown primary allow Stage IV disease Measurable disease physical examination , CT scan , MRI plain xray Unresectable disease Residual recurrent disease prior surgery stage IV disease allow Residual tumor site incomplete resection may include nonmeasurable disease Must serum lactate dehydrogenase ( LDH ) level measure Must tissue specimens available Negative brain CT scan MRI within past 42 day Creatinine = &lt; 1.5 time ULN Absolute neutrophil count &gt; = 1,000/mm^3 Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 9.0 g/dL Fasting cholesterol = &lt; 350 mg/dL ( lipidlowering agent allow ) Triglycerides = &lt; 300 mg/dL ( lipidlowering agent allow ) No symptomatic sensory neuropathy &gt; = grade 2 No evidence bleed diathesis coagulopathy No congestive heart failure No myocardial infarction within past 2 month No New York Heart Association class III IV heart disease No condition impair ability swallow pill ( e.g. , gastrointestinal tract disease result inability take oral medication , requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease ) No know allergy imidazole ( e.g . clotrimazole , ketoconazole , miconazole , econazole ) No history allergic reaction compound similar chemical biologic composition tipifarnib No hypertension systolic blood pressure ( BP ) &gt; 140 mm Hg diastolic BP &gt; 90 mm Hg Patients wellcontrolled hypertension allow Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled diabetes No uncontrolled diabetes No active uncontrolled infection No severe uncontrolled medical disease No psychologic medical condition would preclude study treatment compliance No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , adequately treated stage I II cancer complete remission , carcinoma situ cervix At least 90 day since prior adjuvant therapy , include cytotoxic agent At least 28 day since prior radiotherapy At least 28 day since prior surgery remove tumor No prior systemic therapy stage IV melanoma No prior therapy agent target farnesyl transferase , MAP kinase pathway , vascular endothelial growth factor ( VEGF ) receptor ( VEFGR ) , include drug sorafenib , temsirolimus , tipifarnib Concurrent lipidlowering agent allow Not require fulldose anticoagulation recent thrombotic event No concurrent highly active antiretroviral therapy ( HAART ) HIVpositive patient No concurrent use follow : dilantin ; carbamazepine ; Phenobarbital ; rifampin ; hypericum perforatum ( St. John 's wort ) ; ketoconazole ; itraconazole ; ritonavir ; cyclosporine ; phenytoin ; grapefruit juice Bilirubin = &lt; 1.5 time upper limit normal ( ULN ) SGOT SGPT = &lt; 2.5 time ULN ( 5 time ULN hepatic metastasis ) No history brain metastasis Zubrod performance status 01</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>